To include your compound in the COVID-19 Resource Center, submit it here.

Synagis palivizumab: Phase IV data; Marketed

In an outcomes survey of 2,830 patients treated with Synagis in the U.S. during the

Read the full 150 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE